Manipulating the immune system by interleukin-2 (IL-2) based immunotherapy may induce durable tumour regression in metastatic renal cell carcinoma (mRCC) (Minasian et al, 1993; Fyfe et al, 1995; Jeal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results